EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development of a chimeric hemagglutinin-based live-attenuated influenza vaccine against both lineages of influenza B virus

Pei-Fong Wong, Ekaterina A. Stepanova, Ekaterina A. Bazhenova, Svetlana A. Donina, Larisa G. Rudenko, Irina N. Isakova-Sivak

Medical academic journal · 26.06.2025 · 25 (2) · 33-46

DOI: 10.17816/maj636873 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical academic journal, online erschienen am 26.06.2025. Verfasst von Pei-Fong Wong und 5 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The development of a universal influenza vaccine remains a critical goal to enhance protection against diverse influenza virus strains. While vaccines against influenza type A viruses have benefited from the use of chimeric hemagglutinin designs, strategies for influenza type B vaccines still lag. AIM: The study aimed to investigate the efficacy of chimeric vaccine strains to induce humoral immune response targeting conserved antigenic sites of influenza type B virus. METHODS: A chimeric hemagglutinin was engineered by combining the head domain from the B/Brisbane/60/2008 virus (Victoria lineage) with the stalk domain from the B/Phuket/3073/2013 virus (Yamagata lineage). The gene encoding the chimeric hemagglutinin was incorporated into a vaccine virus based on the cold-adapted B/USSR/60/69 master donor virus to produce live-attenuated influenza vaccine. Mice were sequentially vaccinated with the conventional live-attenuated influenza vaccine and then with the recombinant live-attenuated influenza vaccine expressing the chimeric hemagglutinin. Immune responses and cross-protection against both homologous and heterologous influenza type B virus strains were assessed. RESULTS: The engineered chimeric hemagglutinin did not impair the replication or assembly of the vaccine virus. Sequential vaccination induced a robust humoral immune response and provided protection against both homologous and heterologous influenza type B virus strains in the mouse model. CONCLUSION: Live-attenuated influenza type B vaccines expressing chimeric hemagglutinin show promise in broadening protection against influenza type B virus infection. These findings support the development of a universal influenza type B vaccine using a chimeric hemagglutinin design.

Zitieren

APA

Wong, P., Stepanova, E. A., Bazhenova, E. A., Donina, S. A., Rudenko, L. G., & Isakova-Sivak, I. N. (2025). Development of a chimeric hemagglutinin-based live-attenuated influenza vaccine against both lineages of influenza B virus. Medical academic journal, 25(2), 33-46. https://doi.org/10.17816/maj636873

Vancouver

Wong P, Stepanova EA, Bazhenova EA, Donina SA, Rudenko LG, Isakova-Sivak IN. Development of a chimeric hemagglutinin-based live-attenuated influenza vaccine against both lineages of influenza B virus. Medical academic journal. 2025;25(2):33-46. doi:10.17816/maj636873

BibTeX
@article{Wong2025,
  author = {Wong, Pei-Fong and Stepanova, Ekaterina A. and Bazhenova, Ekaterina A. and Donina, Svetlana A. and Rudenko, Larisa G. and Isakova-Sivak, Irina N.},
  title = {Development of a chimeric hemagglutinin-based live-attenuated influenza vaccine against both lineages of influenza B virus},
  journal = {Medical academic journal},
  year = {2025},
  volume = {25},
  number = {2},
  pages = {33--46},
  doi = {10.17816/maj636873}
}
Kostenlos starten →